Paraprotein levels in assessing effectiveness of polychemotherapy plus selective plasma exchange for multiple myeloma patients.

被引：0
|
作者：
Lysenko, Irina B.
Guskova, Nailya
Kit, Oleg Ivanovich
Ushakova, Natalya Dmitrievna
Golomeeva, Nadezhda
Zuderman, Natalia
Guskova, Ekaterina
Nozdricheva, Anastasia
Abakumova, Svetlana V.
Donskaya, Aliya K.
Gusareva, Marina A.
Avanesova, Kristina
Torpudzhyan, Izabella
Tselishcheva, Irina V.
Zakharchenko, Viktoria
Belgova, Svetlana V.
Gornostaeva, Ekaterina
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e19511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19511
引用
收藏
页数：5
相关论文
共 50 条
  • [21] THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR plus GCSF VERSUS GCSF ± CHEMOTHERAPY AS SALVAGE MOBILIZATION REGIMENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS
    Tuffaha, H. W.
    Hussein, A. A.
    Sharma, S.
    Abu-Jazar, H.
    Al-Rawi, O. S.
    Saad, A. M.
    Al-Zaben, A.
    Hussein, N.
    Abdel-Rahman, F. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S247 - S247
  • [22] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
  • [23] HIGH PLASMA FIBRONECTIN LEVELS IN MULTIPLE-MYELOMA PATIENTS - POSSIBLE MECHANISMS AND CLINICAL IMPLICATIONS
    PAIZI, M
    MANASTER, J
    QUITT, M
    SPIRA, G
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1991, 34 (03) : 285 - 289
  • [24] Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma
    Emechebe, Nnadozie
    Kumar, Shaji
    Goldschmidt, Hartmut
    Victoria Mateos, Maria
    Du, Juan
    Kim, Kihyun
    Merlini, Giampaolo
    Dimopolous, Meletios A.
    Ludwig, Heinz
    Handa, Hiroshi
    Fernandez de Larrea, Carlos
    Reece, Donna E.
    Chen, Wenming
    Raje, Noopur S.
    Karve, Sudeep
    Arriola, Emma
    Ross, Jeremy A.
    Durie, Brian G. M.
    BLOOD, 2021, 138
  • [25] Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange
    Costa, Luciano J.
    Abbas, Jonathan
    Ortiz-Cruz, Karen L.
    Kang, Yubin
    Stuart, Robert K.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (05) : 432 - 434
  • [26] Detection of circulating aneuploid CD38+plasma cells and CD19+lymphocytes in multiple myeloma patients.
    Consoli, U
    Santonocito, AM
    Bagnato, S
    Di Raimondo, F
    Palumbo, G
    Stagno, F
    Guglielmo, P
    Giustolisi, R
    BLOOD, 2000, 96 (11) : 273B - 273B
  • [27] Efficacy of therapeutic plasma exchange in the treatment of multiple myeloma patients with hyperviscosity syndrome: a single-centre experience
    Cvetkovic, Z.
    Kulic, A.
    Markovic, R.
    Strugar, A.
    LEUKEMIA RESEARCH, 2019, 85 : S36 - S36
  • [28] Amifostine pretreatment for protection against Melphalan plus Busulfan-induced toxicity in high-dose therapy for multiple myeloma patients.
    Patriarca, F
    BLOOD, 1999, 94 (10) : 404B - 404B
  • [29] Use of melphalan 280 MG/M2 plus amifostine cytoprotection and autologous stem cell transplantation in multiple myeloma patients.
    Reece, DE
    Filicko, J
    Flomenberg, N
    Howard, DS
    Meisenberg, B
    Plummer, B
    Vesole, D
    Xun, CQ
    Phillips, GL
    BLOOD, 2001, 98 (11) : 196A - 196A
  • [30] Modification of cytokine levels and CD34+stem cell adhesion molecules during mobilization in multiple myeloma (MM) patients.
    Zappasodi, P
    Corso, A
    Rusconi, C
    De Amici, M
    Consensi, E
    Pascutto, C
    Varettoni, M
    Mangiacavalli, S
    Pica, G
    Lazzarino, M
    BLOOD, 2005, 106 (11) : 349B - 349B
12345